Filing Flows › Industrials › Charles River Laboratories International (CRL)
Charles River Laboratories International (CRL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Charles River Laboratories International (CRL) Q3 2026 earnings results →
Q3 2026 Revenue down 2% year over year to $983M · 34¢ of every $1 of revenue kept as net profit · operating margin 20.6%
Charles River Laboratories International made $983M in Q3 2026 (-2% Y/Y): DSA $596M, RMS $208M, Manufacturing $179M. Operating margin 20.6%, net earnings $333M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $982.7M in Q3 2026, down 2% year over year and down 2% from the previous quarter. DSA was the largest line at 61% of revenue. Manufacturing lost $11.8M year over year (down 6%), 53% of the total change.
Operating profit was $202.6M, a 20.6% margin (up 7.3 points year over year). Total costs fell 10% while revenue fell 2%. Net earnings were $333.1M, up 512% year over year. The effective tax rate was -96.0%.
Operating cash flow was $254.1M (up 19% year over year), 76% of net earnings. Non-cash charges added back $72.3M of depreciation and amortization and $20.8M of share-based compensation. Working capital and other items used $173.4M. Capital expenditures of $46.8M left free cash flow of $207.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $983M | -2% | 20.6% | $333M | $254M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $1.0B | -3% | 11.9% | −$760K | $180M |
| Q1 2026 | 10-Q | May 7, 2026 | $996M | +1% | 12.0% | −$14.8M | $41.1M |
| Q4 2025 | 10-K | Feb 18, 2026 | $994M | -0.8% | -28.5% | −$276M | $148M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $1.0B | -0.5% | 13.3% | $54.4M | $214M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $1.0B | +0.6% | 9.7% | $52.7M | $205M |
| Q1 2025 | 10-Q | May 7, 2025 | $984M | -3% | 7.6% | $25.5M | $172M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Charles River Laboratories International
This Annual Report on Form 10-K contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “likely,” “may,” “designed,” “would,” “future,” “can,” “could” and other similar expressions, which are predictions of, indicate future events and trends or which do not relate to historical matters are intended to identify such forward-looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict.
In its own words, from its 10-K, filed Feb 18, 2026.
Charles River Laboratories International against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +8%. Operating margin: 20.6% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
| BIAF bioAffinity Technologies | Q3 2026 | $1.1M | -26% | -328.0% |
Source: Charles River Laboratories International 10-Q on SEC EDGAR · CIK 1100682 · Services-Commercial Physical & Biological Research
Guidance and outlook
13F: who owns CRL and who is buying
More on CRL
- How Charles River Laboratories International makes money: revenue by segment
- Charles River Laboratories International next earnings date and what analysts expect
- Charles River Laboratories International stock forecast, price target and fair value
- Who owns Charles River Laboratories International stock: holders, funds and Congress trades
- Charles River Laboratories International guidance and outlook
- Is Charles River Laboratories International a takeover target? LBO and rumors
- Charles River Laboratories International recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Charles River Laboratories International guidance history: guided vs reported
- Charles River Laboratories International operating margin by quarter
- Charles River Laboratories International net income by quarter
- Charles River Laboratories International free cash flow by quarter
- Charles River Laboratories International capital expenditures by quarter
- Charles River Laboratories International DSA revenue by quarter
- Charles River Laboratories International RMS revenue by quarter
- Charles River Laboratories International Manufacturing revenue by quarter